A Phase III Randomized, Double-Blind, Placebo Controlled, 2 Period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 microg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Phase III Randomized, Double-Blind, Placebo Controlled, 2 Period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 microg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 14 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
    • 18 Dec 2009 Actual patient number (90) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to completed 1 Jan 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top